Table 2.
Adverse events reported in MS patients following COVID-19 vaccination.
| First COVID-19 vaccination dose | Second COVID-19 vaccination dose | |
|---|---|---|
| Study population | 555 | 435 |
| Any adverse events, n (%) | 165 (29.7) | 175 (40.2) |
| Pain at the injection site | 89 (16) | 62 (14.2) |
| Fever/chills, flu-like symptoms | 11 (2) | 52 (11.9) |
| Fatigue | 51 (9.2) | 69 (15.9) |
| Headache | 25 (4.5) | 32 (7.3) |
| Muscle or joint pain | 13 (2.2) | 40 (9.2) |
| Infection with SARS-CoV-2 after vaccination, n (%) | 3 (0.5) | 0 |
| New or worsening neurological symptomatology, n (%) | 11 (2) | 21 (4.8) |
| Face tingling | 3 (0.5) | 5 (1.1) |
| Acute MS relapses, n (%)* | 8 (2.1) | 5 (1.6) |
| Time to relapse, days | ||
| Median | 16 | 15 |
| Range | 10–19 | 14–21 |
MS: multiple sclerosis.
*
Calculated as the number of patients who presented with an acute relapse out of the vaccinated group of RRMS patients.